The available data to date from secondary or sub‐analyses of trials, simulation‐type analyses from recent studies and real‐world data suggest potential complementary and additive effects and in our opinion combination treatment GLP‐1 RA and SGLT‐2 inhibitors should be considered early in the management of CKD in people with diabetes.10 Here, GLP1R is linked to chronic kidney disease.